11
A breakthrough experimental drug has raised new hope in the fight against pancreatic cancer, one of the world’s deadliest malignancies, after clinical trial results showed that patients receiving the treatment lived nearly twice as long as those undergoing conventional chemotherapy.
The drug, known as daraxonrasib, targets a mutated protein responsible for driving tumor growth in more than 90 percent of pancreatic cancer cases. Researchers say the treatment represents a major advance against a disease that has long resisted effective therapeutic options.
The findings, published in the New England Journal of Medicine and presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, stem from a study involving 500 patients with metastatic pancreatic cancer whose disease had stopped responding to previous treatments.
Patients who received the daily oral medication survived for a median of 13.2 months, compared with 6.7 months for those treated with additional chemotherapy. Researchers noted that the drug also resulted in fewer severe side effects and improved quality of life, with many patients reporting reduced pain and shrinking tumors.
Dr. Zev Wainberg of the University of California, Los Angeles, one of the study’s lead investigators, described the results as a major milestone. While emphasizing that the treatment is not a cure, he said it represents a substantial step forward in a field that has seen limited progress for decades.
Cancer specialists have welcomed the findings with optimism. Dr. Rachna Shroff of the University of Arizona Cancer Center, who was not involved in the research, said the durability of the drug’s benefits and the ability of patients to remain on treatment for extended periods were particularly encouraging.
Many participants continued taking daraxonrasib beyond the study’s initial analysis period, suggesting that the survival advantage may increase further as long-term data becomes available.
The study was presented by Dr. Brian Wolpin of the Dana-Farber Cancer Institute, who argued that the drug has the potential to become a new standard treatment for patients with previously treated metastatic pancreatic cancer. Researchers are also planning to investigate whether the therapy could be used earlier in the course of the disease, potentially shrinking tumors enough to make surgery possible for more patients.
The most common side effects linked to the medication included skin rashes and mouth sores, though researchers reported that overall tolerability was better than standard chemotherapy.
Developed by Revolution Medicines, daraxonrasib has attracted significant attention from both physicians and patients. The U.S. Food and Drug Administration (FDA) has indicated that it will expedite its review of the drug, while also permitting expanded access for eligible patients before formal approval.
Pancreatic cancer remains one of the most lethal cancers due to its tendency to spread before symptoms become apparent. According to the American Cancer Society, approximately 67,000 new cases are expected to be diagnosed in the United States this year, with more than 52,000 deaths projected. The overall five-year survival rate remains only 13 percent.
A key reason for the excitement surrounding daraxonrasib is its ability to target KRAS mutations, a long-recognized driver of pancreatic cancer. For years, scientists considered KRAS proteins effectively “undruggable” because of their molecular structure, which made them difficult for medications to bind to successfully.
Daraxonrasib overcomes this challenge through a novel mechanism often described as a molecular glue, enabling it to attach to multiple KRAS subtypes and block their cancer-promoting activity. Researchers are now investigating whether the drug performs better against specific KRAS variants and how it might be combined with other emerging therapies.
Experts believe the findings could mark a turning point in pancreatic cancer research, with dozens of additional experimental treatments currently under development. These include next-generation KRAS inhibitors and innovative cancer vaccines designed to train the immune system to recognize and attack tumor cells.
While further research is needed and regulatory approval is still pending, the success of daraxonrasib has renewed optimism among oncologists and patients alike that meaningful progress against one of the most challenging forms of cancer may finally be within reach.
